Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins to Validate Colorectal Biomarkers with Fox Chase Cancer Center

NEW YORK, June 13 (GenomeWeb News) - Miraculins, a cancer biomarker discovery firm, said today that it will collaborate with FoxChaseCancerCenter to validate markers in a colorectal cancer diagnostic project.


Miraculins picked up the biomarkers in its acquisition of Europroteome's IP portfolio last June.


Under the terms of the agreement, FoxChaseCancerCenter will provide a "significant number" of biological samples, which Miraculins will process with its BEST platform, which combines proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.


The company said that its test has sensitivity and specificity of more than 80 percent.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more